System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Anne-Sophie Defachelles is an expert in Oncology at Centre Oscar Lambret (France). As of October 2026, ScienceLeadR ranks Anne-Sophie Defachelles in the top 1% of experts worldwide for Neuroblastoma. Anne-Sophie Defachelles has authored 135 publications, the most recent in 2026, and is an investigator in 16 clinical trials, 3 of them ongoing. SLR score: 585 (community average: 125). How the SLR is computed.

LeadR Profile

Anne-Sophie Defachelles Centre Oscar Lambret France
585 ScienceLeadR Reputation 585

Unlock

Register Login
Network Map

Oncology

Subspecialties: Pediatrics - Hematology - Neurology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1996 - 2026
Source: PubMed

Centre Oscar Lambret

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 135

Citations

Citations: 2 623 1st author: 10 Last author: 14 Unique author: 0

Main journals

J Clin Oncol 17
Pediatr Blood Cancer 16
Eur J Cancer 10
Bull Cancer 9
Arch Pediatr 6

Best Journals

J Clin Oncol 9
Ann Oncol 1
Lancet Child Adolesc Health 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Insights into rhabdomyosarcoma in the adolescent and young adult population: a comprehensive clinical study from the French Society of Pediatric Oncology (SFCE) Malignant Mesenchymal Tumor (MMT) Committee and the French Sarcoma Group (GSF-GETO).
PMID 42735453 — rhabdomyosarcoma, neoplasms, drug therapy, sarcoma, aged, adolescent, therapeutics, prognosis, chemotherapy		ESMO Open20260
Challenges and needs among pediatric oncology providers in caring for pediatric brain tumor patients and survivors: A qualitative study.
PMID 42306556 — brain neoplasms, communication, brain, neoplasms		Int J Clin Health Psychol20261
Andrological Outcomes in Boys Undergoing Testicular Tissue Extraction Prior to Gonadotoxic Treatment: Evolution During Peripuberty and Young Adulthood.
PMID 41531262 — endocrinology, cells, fertility, puberty, microscopy, electron, scanning transmission, fertility preservation, cryopreservation, inhibins, therapeutics, tissues, semen analysis		Clin Endocrinol (Oxf)20260
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.
PMID 41385757 — temozolomide, cyclophosphamide, drug therapy, neuroblastoma, child, chemotherapy		J Clin Oncol Top journal20250
Childhood, Adolescent and Young Adult Poor-Prognosis Rhabdomyosarcoma.
PMID 41097629 — radiotherapy, rhabdomyosarcoma, drug therapy, sarcoma, adolescent, therapeutics, prognosis, child, chemotherapy		Cancers (Basel)20251

Clinical Studies 16

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4

By phase:

Phase 1/Phase 2 6
N/A 4
Phase 2 2
Phase 3 2
Phase 1 1
Phase 4 1

By status:

Recruiting 8
Completed 6
Not yet recruiting 1
Unknown 1

By type:

Interventional 14
Observational 2

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 1
multicentric5to9 3
multicentricup10 11

Main Topics

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
HR NBL2 High risk neuroblastoma study 2 0 of SIOP Europe Neuroblastoma SIOPEN Randomised international and multicentric phase 3 study that evaluates 3 therapeutic phases (induction high dose chemotherapy and radiotherapy) for patients with high risk neuroblastoma and introduces chemoimmunotherapy for patients with insufficient metastatic response after induction chemotherapy
2024-514917-36-00 — radiotherapy, induction chemotherapy, drug therapy, therapeutics, neuroblastoma, chemotherapy		Phase 3Recruiting2024
Phase Ib study combining dinutuximab beta with induction chemotherapy regimens in patients with newly diagnosed high risk neuroblastoma
2023-509673-22-00 — induction chemotherapy, drug therapy, neuroblastoma, chemotherapy		Phase 1/Phase 2Not yet recruiting2024
SIOPEN BIOPORTAL An International Registry Linked to a Virtual Biobank for Patients With Peripheral Neuroblastic Tumours
NCT05192980 — registries, blood, neoplasms, ganglioneuroblastoma, therapeutics, neuroblastoma, ganglioneuroma		N/ARecruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS